| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8744954 | Clinical Microbiology and Infection | 2018 | 37 Pages |
Abstract
Specific management strategies should be put in place to reduce the risk and/or the severity of infectious complications associated to the reviewed agents.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
![ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33,](/preview/png/8744954.png "First Page Preview: ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33,")
Authors
L. Drgona, C. Gudiol, S. Lanini, B. Salzberger, G. Ippolito, M. Mikulska,